ArticleReproductive sciences (Thousand Oaks, Calif.)2025
Enhanced Improvement of Menstrual Blood Derived Endometrial Stem Cells Encapsulated in Cross-Linked Hyaluronic Acid on Intrauterine Adhesions.
Article in Reproductive sciences (Thousand Oaks, Calif.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Intrauterine adhesions (IUA), characterized by fibrotic adhesions within the uterine cavity, frequently result in menstrual irregularities, recurrent miscarriages, secondary infertility, and increased pregnancy risks among women of childbearing age. Unfortunately, conventional clinical interventions mainly including surgical separation and physical isolation exhibit limited efficacy in promoting the regeneration of the injured endometrium and are associated with a high recurrence rate. Consequently, it is imperative to investigate novel therapies aimed at repairing the injured endometrium in IUA patients, particularly those desiring fertility. Recently, stem cell-based therapies have exhibited promise due to their superior paracrine action and immunomodulation, emerging as a new alternative for tissue regeneration and anti-fibrosis treatment. Herein, we first confirmed the excellent biocompatibility of menstrual blood-derived endometrial stem cells (MenSCs) when combined with XLHA-a hyaluronic acid-based scaffold. The 3D microenvironment provided by XLHA enhanced the immunomodulation of MenSCs and prolonged their retention in uterine cavity of IUA mice. Subsequently, MenSCs encapsulated in XLHA exhibited significantly improved therapeutic outcomes compared to MenSCs or XLHA alone. This approach not only facilitated recovery of endometrial morphology and increased the number of endometrial glands but also ameliorated the apoptosis and inflammation in the endometrium of IUA mice. Furthermore, the transplantation of MenSCs encapsulated in XLHA significantly improved fertility outcomes, likely due to the improved endometrial receptivity in IUA mice. In conclusion, this study confirms that the transplantation of MenSCs encapsulated in XLHA effectively ameliorates endometrial injury in IUA mice while elucidating the potential mechanisms involved. This research provides a practical and cost-effective delivery strategy for enhancing the therapeutic efficiency of MenSCs in IUA treatment.
Indexed as
Identifiers
40629242What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.